EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).

被引：1
|
作者：
Mise, Yoshihiro
Hasegawa, Kiyoshi
Oba, Masaru
Yamaguchi, Kensei
Uetake, Hiroyuki
Yoshino, Takayuki
Morita, Satoshi
Takahashi, Keiichi
Unno, Michiaki
Shimada, Yasuhiro
Muro, Kei
Yoshida, Kazuhiro
Mori, Masaki
Baba, Hideo
Shimada, Mitsuo
Saiura, Akio
Matsumura, Masaru
Ishigure, Kiyoshi
Sugihara, Kenichi
Kokudo, Norihiro
机构：
[1] Japanese Fdn Canc Res, Tokyo, Japan
[2] Univ Tokyo, Tokyo, Japan
[3] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[5] Tokyo Med & Dent Univ, Dept Specialized Surg, Tokyo, Japan
[6] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[7] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[8] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Tokyo, Japan
[9] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan
[10] Kochi Hlth Sci Ctr, Kochi, Japan
[11] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[12] Gifu Univ, Grad Sch Med, Dept Surg Oncol, Gifu, Japan
[13] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka, Japan
[14] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan
[15] Tokushima Univ, Tokushima, Japan
[16] Konan Kosei Hosp, Konan, Japan
[17] Tokyo Med & Dent Univ, Tokyo, Japan
[18] Natl Ctr Global Hlth & Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
652
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
    Takahashi, Takao
    Ishida, Kazuyuki
    Emi, Yasunori
    Sakamoto, Michiie
    Imura, Johji
    Aishima, Shinichi
    Muro, Kei
    Uetake, Hiroyuki
    Oki, Eiji
    Katayose, Yu
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    CANCERS, 2022, 14 (18)
  • [2] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Eiji Oki
    Yasunori Emi
    Takeharu Yamanaka
    Hiroyuki Uetake
    Kei Muro
    Takao Takahashi
    Takeshi Nagasaka
    Etsuro Hatano
    Hitoshi Ojima
    Dai Manaka
    Tetsuya Kusumoto
    Yu Katayose
    Toshiyoshi Fujiwara
    Kazuhiro Yoshida
    Michiaki Unno
    Ichinosuke Hyodo
    Naohiro Tomita
    Kenichi Sugihara
    Yoshihiko Maehara
    British Journal of Cancer, 2019, 121 : 222 - 229
  • [3] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Oki, Eiji
    Emi, Yasunori
    Yamanaka, Takeharu
    Uetake, Hiroyuki
    Muro, Kei
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 222 - 229
  • [4] A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
    Uetake, Hiroyuki
    Emi, Yasunori
    Yamanaka, Takeharu
    Muro, Kei
    Oki, Eiji
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial
    Emi, Y.
    Yamanaka, T.
    Muro, K.
    Uetake, H.
    Oki, E.
    Takahashi, T.
    Katayose, Y.
    Yoshida, K.
    Sakamoto, M.
    Aishima, S.
    Ishida, K.
    Imura, J.
    Unno, M.
    Hyodo, I.
    Tomita, N.
    Sugihara, K.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS
    Schwartzberg, L. S.
    Wagner, V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
    Masaru Matsumura
    Kiyoshi Hasegawa
    Masaru Oba
    Kensei Yamaguchi
    Hiroyuki Uetake
    Takayuki Yoshino
    Satoshi Morita
    Keiichi Takahashi
    Michiaki Unno
    Yasuhiro Shimada
    Kei Muro
    Nobuhisa Matsuhashi
    Masaki Mori
    Hideo Baba
    Mitsuo Shimada
    Yoshihiro Mise
    Yoshikuni Kawaguchi
    Tatsuo Kagimura
    Kiyoshi Ishigure
    Akio Saiura
    Kenichi Sugihara
    Norihiro Kokudo
    Langenbeck's Archives of Surgery, 2022, 407 : 1345 - 1356
  • [8] A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
    Matsumura, Masaru
    Hasegawa, Kiyoshi
    Oba, Masaru
    Yamaguchi, Kensei
    Uetake, Hiroyuki
    Yoshino, Takayuki
    Morita, Satoshi
    Takahashi, Keiichi
    Unno, Michiaki
    Shimada, Yasuhiro
    Muro, Kei
    Matsuhashi, Nobuhisa
    Mori, Masaki
    Baba, Hideo
    Shimada, Mitsuo
    Mise, Yoshihiro
    Kawaguchi, Yoshikuni
    Kagimura, Tatsuo
    Ishigure, Kiyoshi
    Saiura, Akio
    Sugihara, Kenichi
    Kokudo, Norihiro
    LANGENBECKS ARCHIVES OF SURGERY, 2022, 407 (04) : 1345 - 1356
  • [9] PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
    Schwartzberg, Lee S.
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Hecht, J. Randolph
    Yu, Hua
    Oliner, Kelly S.
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) : 2240 - +
  • [10] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
    Graham, C. N.
    Hechmati, G.
    Hjelmgren, J.
    De Liege, F.
    Lanier, J.
    Knoof, A.
    Knox, H.
    Barber, B.
    de Pouvourville, G.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
12345